On the basis of the mechanism of action (MoA) of the drug, patients were thought to require continuous eltrombopag therapy to maintain adequate platelet counts; however, during the last decade, there have been several reports of sustained platelet responses in a percentage of ITP patients after eltrombopag or romiplostim (another TPO-RA) discontinuation (Table S1). Here, TPO is linked to autoimmune thrombocytopenic purpura.